–
Статьи в журналах
-
- 2017 Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, phase 3 trial
- Beer T.M., Hotte S.J., Saad F., Alekseev B., Matveev V., Fléchon A., Gravis G., Joly F., Chi K.N., Malik Z., Blumenstein B., Stewart P.S., Jacobs C.A., Fizazi K.
- в журнале Lancet Oncology, издательство The Lancet Publishing Group (United Kingdom), том 18, № 11, с. 1532-1542 DOI